(Q51483637)

English

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.

scientific article published on 8 December 2006

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17160407

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17160407

type 2 diabetes

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

M A Nauck

1

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17160407

S Duran

2

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17160407

D Kim

3

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17160407

D Johns

4

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17160407

J Northrup

5

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17160407

A Festa

6

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17160407

R Brodows

7

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17160407

M Trautmann

8

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17160407

publication date

8 December 2006

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17160407

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17160407

50

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17160407

2

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17160407

259-267

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17160407

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

1 reference

https://api.crossref.org/works/10.1007%2FS00125-006-0510-2

21 January 2018

The revised CONSORT statement for reporting randomized trials: explanation and elaboration

1 reference

https://api.crossref.org/works/10.1007%2FS00125-006-0510-2

21 January 2018

Weight gain as a risk factor for clinical diabetes mellitus in women

1 reference

https://api.crossref.org/works/10.1007%2FS00125-006-0510-2

21 January 2018

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1007%2FS00125-006-0510-2

21 January 2018

Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs

1 reference

https://pubmed.ncbi.nlm.nih.gov/17160407

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/17160407

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

1 reference

https://pubmed.ncbi.nlm.nih.gov/17160407

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/17160407

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement

1 reference

https://pubmed.ncbi.nlm.nih.gov/17160407

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/17160407

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17160407

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use and abuse of HOMA modeling

1 reference

https://pubmed.ncbi.nlm.nih.gov/17160407

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Correct homeostasis model assessment (HOMA) evaluation uses the computer program

1 reference

https://pubmed.ncbi.nlm.nih.gov/17160407

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Beneficial health effects of modest weight loss

1 reference

https://pubmed.ncbi.nlm.nih.gov/17160407

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/17160407

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001

1 reference

https://pubmed.ncbi.nlm.nih.gov/17160407

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/17160407

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The beneficial effects of modest weight loss on cardiovascular risk factors

1 reference

https://pubmed.ncbi.nlm.nih.gov/17160407

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enhancing Incretin Action for the Treatment of Type 2 Diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/17160407

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Premixed insulin analogues for the treatment of diabetes mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/17160407

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/17160407

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Waist circumference and not body mass index explains obesity-related health risk

1 reference

https://pubmed.ncbi.nlm.nih.gov/17160407

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/17160407

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17160407

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incretin mimetics and dipeptidyl peptidase-IV inhibitors: a review of emerging therapies for type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/17160407

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/17160407

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incretin mimetics as emerging treatments for type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/17160407

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs: efficacy, safety, and cost analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/17160407

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/17160407

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A role for glucagon-like peptide-1 in the central regulation of feeding

1 reference

https://pubmed.ncbi.nlm.nih.gov/17160407

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/17160407

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c).

1 reference

https://pubmed.ncbi.nlm.nih.gov/17160407

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats

1 reference

https://pubmed.ncbi.nlm.nih.gov/17160407

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/17160407

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/17160407

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

1 reference

https://pubmed.ncbi.nlm.nih.gov/17160407

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Waist circumference and obesity-associated risk factors among whites in the third National Health and Nutrition Examination Survey: clinical action thresholds.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17160407

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00125-006-0510-2

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17160407

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17160407

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51483637&oldid=2210864898"